摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl) trichloroacetimidate | 136633-04-0

中文名称
——
中文别名
——
英文名称
O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl) trichloroacetimidate
英文别名
O-(2,3,4-tri-O-benzyl-β-L-fucopyranosyl) trichloroacetimidate;2,3,4-tri-O-acetyl-β-L-fucopyranosyl trichloroacetimidate;[(2R,3S,4R,5R,6S)-6-methyl-3,4,5-tris(phenylmethoxy)oxan-2-yl] 2,2,2-trichloroethanimidate
O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl) trichloroacetimidate化学式
CAS
136633-04-0
化学式
C29H30Cl3NO5
mdl
——
分子量
578.92
InChiKey
UKYLUZBNQWVCNG-RBGCBHJMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.5
  • 重原子数:
    38
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.34
  • 拓扑面积:
    70
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Concise synthesis of 2,7-anhydrosialic acid derivatives and its application
    作者:Kesatebrhan Haile Asressu、Cheng-Chung Wang
    DOI:10.1016/j.carres.2017.10.007
    日期:2017.12
    In N-acetylneuraminic acid, apart from O9 and O8, a possible glycosylation site is the O4 position. For example, gangliosides HLG-2 and HPG-7 are considered to be potential lead compounds for carbohydrate-based drug development to treat neural disorders. However, the construction of their α(1 → 4) fucosyl sialic acid and α(2 → 4) linkages between sialic acids is difficult because of the regioselectivity
    N-乙酰神经氨酸中,除O9和O8外,可能的糖基化位点是O4位置。例如,神经节苷脂HLG-2和HPG-7被认为是用于治疗神经疾病的基于碳水化合物的药物开发的潜在先导化合物。然而,由于区域选择性的问题,难以构建它们的α(1→4)岩藻糖基唾液酸唾液酸之间的α(2→4)键。在此,从Neu5Ac甲酯通过全-O-三甲基甲硅烷基化,加热辅助的分子内异头保护(iMAP)和甲硅烷基化三步合成N-乙酰基-2,7-尿酸。iMAP同时规避了2-OH和7-OH的保护。在将8-和9-OH基团保护为亚苄基乙缩醛时,只有4-OH可自由进行糖基化。这些2,7-anhydro-8
  • Synthesis and Evaluation of Biotinylated Bivalent HistoBlood Group Antigens for Capturing Human Noroviruses
    作者:Abasaheb N. Dhawane、Marta Diez-Valcarce、Bharat P. Gurale、Hieu Dinh、Jan Vinjé、Suri S. Iyer
    DOI:10.1021/acs.bioconjchem.6b00226
    日期:2016.8.17
    H-type glycans that have been reported as binding ligands for human noroviruses were synthesized using a modular synthetic strategy. These glycoconjugates were attached to streptavidin-coated magnetic beads and used to recover human norovirus from fecal samples using a magnetic bead-based assay. The biotinylated bivalent glycans synthesized for this study exhibited similar or better capturing ability
    使用模块合成策略合成了一组生物素化的二价H型聚糖(已被报道为人诺如病毒的结合配体)。将这些糖缀合物附着到链霉亲和素包被的磁珠上,并使用基于磁珠的测定法从粪便样品中回收人诺如病毒。与商业化生物素化糖聚合物相比,为这项研究合成的生物素化二价聚糖表现出相似或更好的捕获能力。
  • Synthesis of ABO Histo-Blood Group Type V and VI Antigens
    作者:Peter J. Meloncelli、Todd L. Lowary
    DOI:10.1071/ch09058
    日期:——
    H type V and VI antigens in multi-milligramme quantities as part of an overall goal to prepare all 18 A, B, and H antigens. The A and B type V and VI antigens were prepared with a 7-octen-1-yl linker, to enable future conjugation to a protein or solid support. The H type V and VI antigens were prepared as the octyl glycoside, to facilitate detailed enzyme kinetics studies.
    长期以来,化学家,生物化学家和进化生物学家都对ABO组织血型抗原感兴趣。然而,迄今为止,尽管该小组有可能提供对这些聚糖基序的生物学作用的更详细的了解,但尚未进行所有ABO组织血型组抗原的完整合成。在这里,我们报告以毫克级的数量对A,B和H型V和VI抗原进行化学合成,这是制备所有18种A,B和H抗原的总体目标的一部分。使用7-辛烯-1-基接头制备A型和B型V型和VI型抗原,以便将来与蛋白质或固体支持物结合。H型V和VI型抗原被制备为辛基糖苷,以促进详细的酶动力学研究。
  • PROCESS FOR PRODUCING 2'-O-FUCOSYLLACTOSE
    申请人:BASF SE
    公开号:US20210130384A1
    公开(公告)日:2021-05-06
    The present invention relates to a method for preparing 2′-O-fucosyllactose, the intermediates obtainable by this method and the use of these intermediates. The preparation comprises the reaction of a protected fucose of the general formula (I) with a tri(C 1 -C 6 -alkyl)silyl iodide to give a protected 1-iodofucose followed by the reaction of the protected 1-iodofucose with a compound of the general formula (II), in the presence of at least one base and deprotecting the resulting coupling product to afford 2′-O-fucosyllactose. In this context, the variables are each defined as follows: R a and R b are the same or different and are —C(═O)—C 1 -C 6 -alkyl, or —C(═O)-phenyl, wherein said phenyl is unsubstituted or optionally has 1 to 5 substituents, or R a and R b together are a radical —(C═O)— or a substituted methylene radical —C(R d R e )—, R c is a radical R Si or is benzyl, wherein said benzyl is unsubstituted or optionally has 1, 2 or 3 substituents, R Si is a radical of the formula SiR f R g R h , where R f , R g and R h are the same or different and are C 1 -C 8 -alkyl for example, R 1 is a radical —C(═O)—R 11 or a radical SiR 12 R 13 R 14 R 2 are the same or different and are C 1 -C 8 -alkyl for example; R 3 are the same or different and are for example C 1 -C 8 -alkyl or both radicals R 3 together form a linear C 1 -C 4 -alkenyl, which is unsubstituted or has 1 to 6 methyl groups as substituents.
    本发明涉及一种制备2'-O-岩藻糖乳的方法,以及通过该方法可获得的中间体和这些中间体的用途。该制备包括将一般式(I)的保护岩藻糖与三(C1-C6-烷基)反应,得到保护1-岩藻糖,然后将保护1-岩藻糖与一般式(II)的化合物在至少一种碱的存在下反应,并去保护所得的偶联产物以得到2'-O-岩藻糖。在这种情况下,变量的定义如下:Ra和Rb相同或不同,为—C(═O)—C1-C6-烷基,或—C(═O)-苯基,其中所述苯基未取代或可选地具有1至5个取代基,或者Ra和Rb一起是一个基团—(C═O)—或一个取代亚甲基基团—C(RdRe)—,Rc是基团RSi或苄基,其中所述苄基未取代或可选地具有1、2或3个取代基,RSi是具有式SiRfRgRh的基团,其中Rf、Rg和Rh相同或不同,为C1-C8-烷基,例如,R1是基团—C(═O)—R11或基团SiR12R13R14,R2相同或不同,为C1-C8-烷基,例如,R3相同或不同,例如为C1-C8-烷基,或两个基团R3一起形成未取代或具有1至6个甲基基团作为取代基的线性C1-C4-烯基。
  • Glycosides of 8-hydroxy-3,6-dioxaoctanal. A synthesis of a new spacer for synthetic oligosaccharides
    作者:Vicente Verez-Bencomo、Maria T. Campos-Valdes、Jose R. Mariño-Albernas、Violeta Fernandez-Santana、Marilyn Hernandez-Rensoli、Carlos S. Perez-Martinez
    DOI:10.1016/0008-6215(91)84138-5
    日期:1991.9
查看更多